Varicella-zoster virus as a live recombinant vaccine

Details Varicella-zoster virus as a live recombinant vaccine Varicella-zoster virus as a live recombinant vaccine

C - Chemistry, Metallurgy

12

N

167/130, 195/1.2

C12N 7/01 (2006.01) A61K 39/245 (2006.01) A61K 39/29 (2006.01) A61K 39/295 (2006.01) C07K 14/02 (2006.01) C07K 14/03 (2006.01) C12N 15/86 (2006.01) C12N 15/869 (2006.01) A61K 39/00 (2006.01)

Patent

CA 1337596

A vaccine strain of varicella-zoster virus (VZV), tested in clinical trials, is capable of preventing chickenpox in children. This virus has been modified by the introduction into its genome of heterologous DNA which encodes an immunogenic polypeptide of another human pathogen. This heterologous polypeptide is expressed in cells infected by the recombinant virus. Such recombinant VZV is useful as a vaccine for chickenpox as well as for heterologous pathogens.

539785

Affiliated with

Also associated with

Rating

Varicella-zoster virus as a live recombinant vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Varicella-zoster virus as a live recombinant vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Varicella-zoster virus as a live recombinant vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1171361